Education
About Us
Working with TipRanks
Follow Us
Collegium Pharmaceutical (COLL)
NASDAQ:COLL
COLL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$23.23 - $42.29
Previous CloseN/A
Volume233.62K
Average Volume (3M)464.60K
Market Cap
$845.07M
Enterprise Value$1.94B
Total Cash (Recent Filing)$1.63M
Total Debt (Recent Filing)$13.01M
Price to Earnings (P/E)14.2
Beta0.23
Next Earnings
May 08, 2025EPS Estimate
1.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.85
Shares Outstanding32,131,798
10 Day Avg. Volume455,098
30 Day Avg. Volume464,595
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)N/A
Price to Sales (P/S)1.50
Price to Cash Flow (P/CF)2.80
P/FCF Ratio2.80
Enterprise Value/Market Cap2.30
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.14
Enterprise Value/Ebitda6.85
Forecast
1Y Price Target
$43.00Price Target Upside63.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Collegium Pharmaceutical News
PremiumCompany Announcements
Collegium Pharmaceutical Appoints New Executive VP and General Counsel
PremiumCompany Announcements
Collegium Pharma’s Earnings Call Highlights Growth and Strategy
PremiumCompany Announcements
Collegium Pharmaceutical Reports Record 2024 Financial Results---
Bulls Say, Bears Say
Bulls Say
Growth ProspectsJornay PM is highlighted as a key growth driver for the company.
Product PortfolioThe company has a strong and diverse product portfolio with high-confidence longer exclusivity for products like Belbuca, JORNAY PM, and XTAMPZA ER, potentially extending exclusivity well into the future.
ValuationCollegium Pharmaceutical Inc. trades at a low valuation of only 3.7 times the midpoint of its 2025 EV/EBITDA guidance, which is attractive given its history of exceeding EBITDA guidance for the past three years.
Bears Say
Generic Competition RiskDespite potential risks from generic competition, Collegium is projected to generate significant cumulative adj-EBITDA and operating cash flow through 2028, which exceeds its current enterprise value.
Seasonal Sales ImpactA small adjustment is made to reflect the expected seasonal slowdown in sales due to Rx re-authorizations and insurance deductible resets.
SeasonalitySeasonality factors typically lead to a revenue step-down in the first quarter, affecting the company's financial performance compared to the fourth quarter.
---
Ownership Overview
4.44% Insiders
37.98% Mutual Funds
0.90% Other Institutional Investors
24.03% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
COLL FAQ
What was Collegium Pharmaceutical’s price range in the past 12 months?
Collegium Pharmaceutical lowest stock price was $23.23 and its highest was $42.29 in the past 12 months.
What is Collegium Pharmaceutical’s market cap?
Collegium Pharmaceutical’s market cap is $845.07M.
When is Collegium Pharmaceutical’s upcoming earnings report date?
Collegium Pharmaceutical’s upcoming earnings report date is May 08, 2025 which is in 24 days.
How were Collegium Pharmaceutical’s earnings last quarter?
Collegium Pharmaceutical released its earnings results on Feb 27, 2025. The company reported $1.77 earnings per share for the quarter, beating the consensus estimate of $1.538 by $0.232.
Is Collegium Pharmaceutical overvalued?
According to Wall Street analysts Collegium Pharmaceutical’s price is currently Undervalued.
Does Collegium Pharmaceutical pay dividends?
Collegium Pharmaceutical does not currently pay dividends.
What is Collegium Pharmaceutical’s EPS estimate?
Collegium Pharmaceutical’s EPS estimate is 1.79.
How many shares outstanding does Collegium Pharmaceutical have?
Collegium Pharmaceutical has 32,131,798 shares outstanding.
What happened to Collegium Pharmaceutical’s price movement after its last earnings report?
Collegium Pharmaceutical reported an EPS of $1.77 in its last earnings report, beating expectations of $1.538. Following the earnings report the stock price went up 2.217%.
Which hedge fund is a major shareholder of Collegium Pharmaceutical?
Currently, no hedge funds are holding shares in COLL
---
Collegium Pharmaceutical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.00 (63.50% Upside)
$43.00 (63.50% Upside)
Blogger Sentiment
Bullish
COLL Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 97.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.1%
Last 30 Days ▼ 9.0%
Last 30 Days ▼ 9.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.72%
12-Months-Change
Fundamentals
Return on Equity
32.62%
Trailing 12-Months
Asset Growth
45.51%
Trailing 12-Months
Company Description
Collegium Pharmaceutical
Collegium Pharmaceutical, Inc. (COLL) is a specialty pharmaceutical company focused on developing and commercializing innovative medicines for people suffering from serious medical conditions. The company operates primarily in the pain management sector, offering products that address the challenges of opioid therapy. Its flagship product, Xtampza ER, is an extended-release, abuse-deterrent formulation of oxycodone designed for managing chronic pain in patients requiring continuous, long-term opioid treatment.
---
COLL Company Deck
---
COLL Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant growth in Jornay PM and a strong financial position, supported by strategic acquisitions and expansions. Despite a decline in Nucynta revenue and increased operating expenses, the overall outlook remains positive due to strong performance in the pain portfolio and strategic initiatives.Read More>---
COLL Stock 12 Month Forecast
Average Price Target
$43.00
▲(63.50% Upside)
Technical Analysis
Harrow Health
―
Xeris Pharmaceuticals
―
Vir Biotechnology
―
Nurix Therapeutics
―
Mineralys Therapeutics, Inc.
―
Best Analysts Covering COLL
1 Year
1 Year Success Rate
13/32 ratings generated profit
1 Year Average Return
+5.19%
reiterated a buy rating 5 days ago
Copying Serge Belanger's trades and holding each position for 1 Year would result in 40.63% of your transactions generating a profit, with an average return of +5.19% per trade.
---